New immune combo targets deadly childhood brain cancer
NCT ID NCT06514898
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 23 times
Summary
This early-stage study tests a combination of immune therapies in 12 children and young adults (ages 4-30) whose medulloblastoma has come back. The treatment uses specially trained immune cells, a vaccine, and stem cells, along with a drug that helps the immune system attack the tumor. The main goals are to see if this approach is safe and possible to deliver.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GROUP 3 MEDULLOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Florida Health
Gainesville, Florida, 32608, United States
Conditions
Explore the condition pages connected to this study.